Bavarian Nordic (OTCMKTS:BVNRY) Posts Earnings Results

Bavarian Nordic (OTCMKTS:BVNRY) issued its quarterly earnings results on Friday. The company reported $0.46 earnings per share for the quarter, Zacks reports. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.

Bavarian Nordic Trading Up 10.0%

OTCMKTS:BVNRY traded up $0.99 on Friday, reaching $10.95. 23,999 shares of the stock traded hands, compared to its average volume of 3,210. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of 14.41 and a beta of 1.20. The company’s 50 day moving average is $9.27 and its 200-day moving average is $9.68. Bavarian Nordic has a 1-year low of $8.67 and a 1-year high of $13.00.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.